Periodontal Disease Overview
Periodontal diseases are mainly the result of infections and inflammation of the gums and bone that surround and support the teeth. In its early stage, called gingivitis, the gums can become swollen and red, and they may bleed. In its more serious form, called periodontitis, the gums can pull away from the tooth, bone can be lost, and the teeth may loosen or even fall out. Periodontal disease is mostly seen in adults. Periodontal disease and tooth decay are the two biggest threats to dental health.
“Periodontal Disease Pipeline Insight, 2022" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Periodontal Disease Market.
The Periodontal Disease Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Periodontal Disease Pipeline Report:
- Companies across the globe are diligently working toward developing novel Periodontal Disease treatment therapies with a considerable amount of success over the years. Periodontal Disease Key players such as - Vaxcyte, AngioLab, Inc., Cortexyme, Noveome Biotherapeutics, Amyndas Pharmaceuticals, D and D Pharmatech, and others, are developing therapies for the Periodontal Disease treatment
- Periodontal Disease emerging therapies such as - VAX PG, AL102-PDT, COR-588, ST266, AMY-101, P4M01, and others are expected to have a significant impact on the Periodontal Disease market in the coming years.
- On July 22, 2019, Amyndas Pharmaceuticals initiated a Phase II a clinical trial to assess the safety and efficacy of C3 inhibitor AMY-101, in adults with Gingivitis. The phase 2 trial was a 3-month randomized, double-blind, split-mouth study in adults with gingivitis and chronic periodontal inflammation. The two halves of the mouth were randomized in each patient to receive AMY-101 or placebo (split-mouth design)
- In March 2021, Amyndas Pharmaceuticals announced positive top-line Phase II results from its randomized, placebo controlled clinical trial evaluating AMY-101 in 39 patients with periodontal inflammation and gingivitis. AMY-101,administered locally in the affected gingival tissues once a week for three weeks, demonstrated resolution of inflammation as measured by the reduction of bleeding (p < 0.001) and gingival inflammation index (p < 0.001), the main determinants of this condition
Periodontal Disease Pipeline Therapeutics Assessment
- Periodontal Disease Assessment by Product Type
- Periodontal Disease By Stage and Product Type
- Periodontal Disease Assessment by Route of Administration
- Periodontal Disease By Stage and Route of Administration
- Periodontal Disease Assessment by Molecule Type
- Periodontal Disease by Stage and Molecule Type
DelveInsight's Periodontal Disease Report covers around 8+ products under different phases of clinical development like
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I)
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Emerging Periodontal Disease Drugs Under Different Phases of Clinical Development Include:
- VAX PG: Vaxcyte
- AL102-PDT: AngioLab, Inc.
- COR-588: Cortexyme
- ST266: Noveome Biotherapeutics
- AMY-101: Amyndas Pharmaceuticals
- P4M01: D and D Pharmatech
Get a Free Sample PDF Report to know more about Periodontal Disease Pipeline Assessment
Periodontal Disease Pipeline Analysis:
The Periodontal Disease pipeline report provides insights into
- The report provides detailed insights about companies that are developing therapies for the Periodontal Disease treatment with aggregate therapies developed by each company for the same.
- It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Periodontal Disease Treatment.
- Periodontal Disease key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- Periodontal Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Periodontal Disease market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Further Periodontal Disease product details are provided in the report. Download the Periodontal Disease pipeline report to learn more about the emerging Periodontal Disease therapies
Periodontal Disease Pipeline Market Drivers
- Growing awareness about oral hygiene
- Rising geriatric population across the world
Periodontal Disease Pipeline Market Barriers
- High dental treatment costs
- Unfavorable reimbursement scenario
Scope of Periodontal Disease Pipeline Drug Insight
- Coverage: Global
- Key Periodontal Disease Companies: Vaxcyte, AngioLab, Inc., Cortexyme, Noveome Biotherapeutics, Amyndas Pharmaceuticals, D and D Pharmatech, and others
- Key Periodontal Disease Therapies: VAX PG, AL102-PDT, COR-588, ST266, AMY-101, P4M01, and others
- Periodontal Disease Therapeutic Assessment: Periodontal Disease current marketed and Periodontal Disease emerging therapies
- Periodontal Disease Market Dynamics: Periodontal Disease market drivers and Periodontal Disease market barriers
Request for Sample PDF Report for Periodontal Disease Pipeline Assessment and clinical trials
Table of Contents
| 1 | Periodontal Disease Report Introduction |
| 2 | Periodontal Disease Executive Summary |
| 3 | Periodontal Disease Overview |
| 4 | Periodontal Disease- Analytical Perspective In-depth Commercial Assessment |
| 5 | Periodontal Disease Pipeline Therapeutics |
| 6 | Periodontal Disease Late Stage Products (Phase II/III) |
| 7 | Periodontal Disease Mid Stage Products (Phase II) |
| 8 | Periodontal Disease Early Stage Products (Phase I) |
| 9 | Periodontal Disease Preclinical Stage Products |
| 10 | Periodontal Disease Therapeutics Assessment |
| 11 | Periodontal Disease Inactive Products |
| 12 | Company-University Collaborations (Licensing/Partnering) Analysis |
| 13 | Periodontal Disease Key Companies |
| 14 | Periodontal Disease Key Products |
| 15 | Periodontal Disease Unmet Needs |
| 16 | Periodontal Disease Market Drivers and Barriers |
| 17 | Periodontal Disease Future Perspectives and Conclusion |
| 18 | Periodontal Disease Analyst Views |
| 19 | Appendix |
| 20 | About DelveInsight |
Download Sample PDF Report to know more about Periodontal Disease drugs and therapies
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email:Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
